trial

The Effects of Nicotine on Cognition in Schizophrenia

NCTId NCT00383747
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 60 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2009-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2004-04
Primary completion
2009-01
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Transdermal nicotine patch

Sponsors

Massachusetts General HospitalLead Sponsor
Stanley Medical Research InstituteCollaborator
North Suffolk Mental Health AssociationCollaborator

Investigators

1
A. Eden Evins, MD, MPHPrincipal Investigator

Sites

1 total
Boston, United States

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE4
Primary Completion Date
2009-01
Status
COMPLETED
relationships
The graph out of here
drug
Transdermal nicotine patch
drug
lead_sponsor
Massachusetts General Hospital
company
collaborator
Stanley Medical Research Institute
company
North Suffolk Mental Health Association
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
A. Eden Evins, MD, MPH
person